Evans John M. 4
4 · Beam Therapeutics Inc. · Filed Apr 1, 2026
Research Summary
AI-generated summary of this filing
Beam Therapeutics (BEAM) CEO John M. Evans Exercises Options, Sells Shares
What Happened John M. Evans, CEO and director of Beam Therapeutics (BEAM), exercised stock options and sold shares in late March 2026. He exercised 25,000 options on 2026-03-30 and another 25,000 on 2026-03-31 at a $0.67 exercise price (total exercise cost $33,500). He sold 25,000 shares on 2026-03-30 at a weighted-average price of $22.37 (proceeds $559,230) and 25,000 shares on 2026-03-31 at a weighted-average price of $22.76 (proceeds $569,085), for total sale proceeds of approximately $1,128,315. On 2026-03-31 he also received a grant of 90,000 restricted stock units (RSUs) (no cash value at grant).
Key Details
- Transaction dates: 2026-03-30 and 2026-03-31; filing date: 2026-04-01 (period of report 2026-03-30). No late filing indicated in the provided excerpt.
- Sales: 25,000 shares on 3/30 at a weighted avg $22.37 (range $22.03–$22.70 per F2); 25,000 shares on 3/31 at a weighted avg $22.76 (range $22.34–$23.21 per F3).
- Option exercises: 25,000 shares exercised on 3/30 and 25,000 on 3/31 at $0.67 per share (total exercise cost $33,500).
- Award: 90,000 RSUs granted on 3/31 (F4); RSUs vest in four roughly equal annual installments, subject to continued service.
- Sales were made pursuant to a Rule 10b5-1 trading plan adopted May 16, 2025 (F1).
- Shares owned after the transactions are not specified in the provided filing excerpt.
- Footnote F5 references an earlier 2018 option grant and a performance-based vesting that occurred in 2024; not directly altering these March 2026 transactions.
Context
- This filing shows option exercises followed by open-market sales under a pre-established 10b5-1 plan, a common practice for executives to monetize vested equity while avoiding concerns about trading on inside information. The combination of exercise + sale is effectively an exercise-and-sell sequence (proceeds far exceed exercise cost).
- The 90,000 RSU grant is a time-vesting award and does not represent immediate transferable shares; it vests over four years if service conditions are met.
- As always, filings are factual disclosures and do not by themselves indicate the insider’s view of the company’s prospects.
Insider Transaction Report
Form 4
Evans John M.
DirectorCEO
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-30$0.67/sh+25,000$16,750→ 1,011,667 total - Sale
Common Stock
[F1][F2]2026-03-30$22.37/sh−25,000$559,230→ 986,667 total - Exercise/Conversion
Common Stock
[F1]2026-03-31$0.67/sh+25,000$16,750→ 1,011,667 total - Sale
Common Stock
[F1][F3]2026-03-31$22.76/sh−25,000$569,085→ 986,667 total - Award
Common Stock
[F4]2026-03-31+90,000→ 1,076,667 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-03-30−25,000→ 43,672 totalExercise: $0.67Exp: 2028-05-08→ Common Stock (25,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-03-31−25,000→ 18,672 totalExercise: $0.67Exp: 2028-05-08→ Common Stock (25,000 underlying)
Holdings
- 103,000(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.03 to $22.70, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.34 to $23.21, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]Represents restricted stock units ("RSUs") granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.
- [F5]On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.
Signature
By: /s/ Christine Bellon, Attorney-in-fact|2026-04-01